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Abstract
Background: Uncomplicated chronic rachialgia is a highly prevalent complaint, and one for which
therapeutic results are contradictory. The aim of the present study is to evaluate the effectiveness
and safety of treatment with auriculopressure, in the primary healthcare sector, carried out by
trained healthcare professionals via a 30-hour course.
Methods/Design: The design consists of a multi-centre randomized controlled trial, with placebo,
with two parallel groups, and including an economic evaluation. Patients with chronic
uncomplicated rachialgia, whose GP is considering referral for auriculopressure sensory
stimulation, are eligible for inclusion. Sampling will be by consecutive selection, and randomised
allocation to one of the two study arms will be determined using a centralised method, following a
1:1 plan (true auriculopressure; placebo auriculopressure). The implants (true and placebo) will be
replaced once weekly, and the treatment will have a duration of 8 weeks. The primary outcome
measure will be the change in pain intensity, measured on a visual analogue scale (VAS) of 100 mm,
at 9 weeks after beginning the treatment. A follow up study will be performed at 6 months after
beginning treatment. An assessment will also be made of the changes measured in the Spanish
version of the McGill Pain Questionnaire, of the changes in the Lattinen test, and of the changes in
quality of life (SF-12). Also planned is an analysis of cost-effectiveness and also, if necessary, a cost-
benefit analysis.
Discussion: This study will contribute to developing evidence on the use of auriculotherapy using
Semen vaccariae [wang bu liu xing] for the treatment of uncomplicated chronic rachialgia.
Trial registration: Current Controlled Trials ISRCTN01897462.
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Background
Uncomplicated chronic rachialgia (UCR) is characterised
by pain in the vertebral and paravertebral areas, the inten-
sity of which varies depending on postures, movements
and effort. It is usually associated with a painful limitation
of mobility of the spine and sometimes with extensive or
irradiated pain. The diagnosis of such complaints
excludes fractures, direct traumas and systemic disease,
but includes structural alterations of the spine, such as
disc hernias or facetary alterations [1]. However, only 5%
of the mechanical disorders of the spinal column that are
treated in primary healthcare result from a structural alter-
ation of the spine. The remaining 95% are comprised of
non-specific neck and back pains [2]. Of all these loca-
tions, the lumbar region is most prevalent; between 60
and 70% of adults are estimated to have suffered this com-
plaint at some time. Moreover, it tends to be persistent or
recurrent [3] and in 95% of cases it is of non-specific mus-
cular-skeletal origin [4]. In Spain, work time lost due to
back pain is an average of 22 days per year, with an aver-
age cost of 1,260 euros per worker; the complaint repre-
sents 19–25% of the total expenditure on benefits for
temporary sickness pay, and the total effect of back pain
on the workplace has been estimated at an average of
55,388 days lost every year [5]. 90% of the patients with
non-specific back pain return to work within six week [6].
Neck pain, on the other hand, is a problem that has been
estimated to effect, at some time in life, 30% of men and
43% of women [7], becoming chronic among 10% of
men and 17% of women. It is currently the second most
important rheumatic cause for occupational invalidity
[8]. Although the aetiology of neck pain is varied, ranging
from tumoral problems to traumatisms, infections,
inflammatory diseases and congenital diseases, in most
cases no systemic causes can be identified, and so the larg-
est such group is labelled as "non-specific neck pain". A
recent study carried out in Finland estimated the annual
prevalence of back pain to be 17% [9].
The treatment for non-specific back pain is usually con-
servative, and the standard procedure is to recommend
pharmacological treatment with analgesic medication
such as non-opiate analgesics, non steroidal anti-inflam-
matory drugs (NSAIDs), myorelaxants and opiates. The
evidence derived from 51 studies examined in a system-
atic review [10] suggests that NSAIDs are effective for
short-term symptomatic relief for patients with back pain,
but there does not seem to be a specific variety of NSAID
that is clearly more effective than any other. Myorelaxants
are effective in treating non-specific back pain, but their
adverse side effects mean they must be used with caution.
Trials are needed to determine whether myorelaxants are
more effective than analgesics or NSAIDs [11]. Multidisci-
plinary biopyschosocial rehabilitation for sub-acute pain
in adults of working age has been analysed in a systematic
review [12], which concluded that there exists a moderate
degree of proof of the positive effectiveness of multidisci-
plinary rehabilitation. As this evidence is based on studies
that presented some kind of methodological defect, and
as various types of expensive multidisciplinary rehabilita-
tion are commonly employed, there is an obvious need
for high-quality trials to be carried out in this field [13].
Acupuncture and related techniques such as auriculother-
apy have been used as therapeutic methods in China for
over 2000 years, and are gaining increasing acceptance in
the West, where their use has increased considerably in
recent decades, especially for pathologies characterised by
the presence of pain [14]. Stimulation of the auricular
pavilion is usually employed as a technique associated
with somatic acupuncture for alleviating pain, and also
for sleep disorders, anxiety [15,16] or complaints of the
autonomic nervous system [17], but it may also be used
alone for the treatment of diverse muscular-skeletal
pathologies [18-23], probably taking effect by means of
an endorphinergic mechanism [24]. A wide variety of
mappings have been made of the auricular pavilion,
based on a supposed interconnection between the ear and
the rest of the body, such that muscular-skeletal structures
would be reflected, somatotopically, in the auricular
pavilion [25,26]. Thus, any complaint of the muscles or
skeleton would have an accurate representation within
the ear, made evident as an increase in sensitivity to pres-
sure or as a decrease in the electrical resistance of the skin
[27]. The treatment usually consists of locating the sensi-
tive points and then stimulating them with needles, which
may be left in place for several days, or by the implanta-
tion of vaccaria seeds (wang bu liu xing), held within the
auricular pavilion by means of small pieces of surgical
tape. Nevertheless, as yet no clear relation has been deter-
mined between the somatic locations where muscular-
skeletal pain is felt and the sensitive points within the
auricular pavilion [28].
We have designed this randomised controlled multicentre
study to investigate the effectiveness and safety of sensory
stimulation via auricular implants in patients with UCR,
treated by healthcare professionals (15 doctors and
nurses) at 10 healthcare clinics in the Sevilla-Sur Health-
care District (within the Andalusian Public Health Sys-
tem). The primary specific goal is to assess effectiveness in
terms of the lessened pain intensity, measured on a visual
analogue scale (VAS), experienced by patients with UCR,
at 9 weeks after beginning treatment. As secondary spe-
cific goals, we intend to: a) evaluate the effectiveness in
terms of lessened pain intensity, measured on the VAS, at
6 months after beginning treatment; b) evaluate the effec-
tiveness in terms of improvement recorded on the Span-
ish version of the McGill Pain Questionnaire (MPQ-SV),
at 9 weeks and at 6 months after beginning treatment; c)BMC Complementary and Alternative Medicine 2008, 8:36 http://www.biomedcentral.com/1472-6882/8/36
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evaluate the effectiveness in terms of patient-perceived
improvement (PPI) at the end of the treatment; d) evalu-
ate the impact on time lost off work due to sickness; e)
evaluate the credibility of the technique and patients'
expectations, as well as its relation to the results; f) evalu-
ate the effectiveness in terms of reduced consumption of
analgesic and anti-inflammatory medication; g) evaluate
the effectiveness in terms of improved health-related qual-
ity of life (SF-12); h) compare the effectiveness of the tech-
nique with regard to the healthcare professionals' degree
of training and practice; i) compare the characteristics of
the Lattinen test and the MPQ-SV; j) analyze the cost-
effectiveness of treatment with auricular pressure for
patients with UCR.
This study is funded by the Instituto de Salud Carlos III,
Fondo de Investigaciones Sanitarias (File No. PI0790058)
and by the Health Ministry of the Andalusian Regional
Government (File No. 00462007).
Methods
Design
Randomized controlled multicentre prospective study,
with two parallel arms, to compare real auriculotherapy
using vaccaria seeds (in accordance with traditional meth-
ods and with individual diagnoses) and placebo auriculo-
therapy. The patients will be blinded to both treatment
methods. Analysis of the results will be carried out by pro-
fessionals who will be blinded with respect to the alloca-
tion of patients to the different treatment groups.
Duration of Study
May 2008–December 2009
Subjects
Patients, recruited by the 15 doctors and nurses participat-
ing in the study at 10 Primary Healthcare Centers belong-
ing to the Andalusian Public Health System (Sevilla-Sur
Healthcare District), with symptoms of uncomplicated
chronic rachialgia.
The patients included will be aged at least 18 years, with
chronic uncomplicated muscular-skeletal rachialgia
(neck, mid-back or lower back), diagnosed by clinical
background and physical examination, and who have not
previously received treatment with auricular implants.
Exclusion criteria will include the protrusion or prolapse
of one or more intervertebral discs with concurrent neuro-
logical symptoms; infectious spondylopathy; previous
surgery of the spinal column; rachialgia caused by inflam-
matory disease, malign or autoimmmune; congenital
deformities of the spinal column, except mild degrees of
scoliosis or lordosis; vertebral fractures; spinal stenosis;
spondylolysis or spondylolystesis; skin complaints in the
auricular pavilion or allergy to sticking plaster; pregnancy;
lawsuits brought by reason of rachialgia; incapacity to fill
in the questionnaires or respond to the evaluator's ques-
tions.
The ethical validity of this study has been analyzed and
approved by the Andalusian Government Committee for
Clinical Trials, following the approval of the correspond-
ing Research Commission at each of the participating
Clinics. The study design takes into account the funda-
mental principles set out in the Helsinki Declaration, and
those of the Council of Europe Convention concerning
human rights and biomedicine, as well as the require-
ments under Spanish law in the field of biomedical
research, the protection of personal data, and bioethics.
All the patients involved must sign their informed consent
to the proposed clinical research procedures. During the
course of the study, audits will be performed as required
by the relevant Research and Ethics Committee, as well as
those of each Clinic's Quality Committee, independently
of any external audits (such as that of the research financ-
ing body) that may be necessary.
Randomization and treatment allocation
Sampling will be by consecutive selection in accordance
with the inclusion-exclusion criteria, for a period of 12
months until the sample is complete. The randomized
allocation to each of the two branches of the study will be
carried out using specialized computer software (Epidat v.
3.1), at the Research Unit of the Costa del Sol Hospital
(Málaga, Spain), in a 1:1 plan (true auricular pressure: pla-
cebo) in blocks of 6, stratified by therapist. Neither the
clinics nor the healthcare professional participating in the
study will be involved in the randomization process, and
the randomization sequence will remain concealed until
the end of the study. Patients who meet the criteria for
inclusion and who sign their informed consent will be
included in the study. After inclusion in the study, the
healthcare professional will call the randomization clinic
at which the patient is registered, and will be informed,
both by phone and by fax, which of the two study
branches the patient has been assigned to. This procedure
ensures that the randomization process is not influenced
by the healthcare personnel participating in the study. The
success of the blinding of the patients will be evaluated at
the end of the treatment period.
Sample size
In calculating the sample size, a power of 90% and an α
value of 5% were assumed, to detect a mean change in
pain intensity, measured on the 100 mm visual analogue
scale, of 32.3 mm between the initial and final values
among the experimental group, and a mean reduction of
19.8 mm among the control group (standard deviation
31.9 mm), on the basis of the results of a pilot experiment
carried out beforehand at the Pain Treatment Unit at theBMC Complementary and Alternative Medicine 2008, 8:36 http://www.biomedcentral.com/1472-6882/8/36
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Dos Hermanas Healthcare Clinic between April and
December 2006. These assumptions require a sample size
of 140 patients per group, in a design with two equal
groups. We propose to recruit 400 patients in order to
allow for a 30% drop out rate.
Treatment
The 15 healthcare professionals who will participate in
the study (doctors and nurses) have taken a training
course in auricular pressure techniques for the treatment
of UCR, with a total of 15 hours' theory and 15 hours'
practical content. Of these 15 professionals, 5 had also
received specific training in acupuncture and related tech-
niques, with an average of 320 hours theoretical training
and over 100 hours' clinical practice with these tech-
niques. All the patients will be allowed to use sympto-
matic medication for pain relief in case of need.
The patients in both groups will be called 8 times for treat-
ment (once a week) for the auricular implants to be
inserted.
A) True auriculotherapy using pressure with vaccaria seeds (TAP)
Application of auricular implants with vaccaria seeds (vac-
caria segetalis Garcke, known in China as Wang bu liu
xing) as an individualized form of sensory stimulation,
affixed to the auricular pavilion by means of flesh-col-
oured sticking plaster. Selection of the auricular points
will be made in accordance with the pain characteristics
and the sensitivity of the auricular zones, examined using
a 250 gr pressure detector [[26], 29]. The patients will be
requested to squeeze the implant with their finger 10
times, 3 times a day. These implants will remain in place
for one week.
B) Placebo auriculotherapy (PAP)
The same protocol will be followed, under the same con-
ditions as for TAP, but with the application of sticking
plaster over inactive black plastic discs, with a diameter of
1.5 mm, simulating the appearance of the auricular
implants used in the TAP.
Any adverse reactions or side effects that may occur will be
recorded in the corresponding data logbook, stating
details of the reaction, and date of occurrence.
The same time should be dedicated to the patients in each
of the groups, as should that employed in the pre and
post-session evaluations (Fig. 1).
Results measures
Each patient will fill in a self-response questionnaire
before beginning the treatment (T0), at one week after
ending treatment (T1) and after six months (T2). This
questionnaire will include one-dimensional data (100
mm visual analogue scale) and multidimensional data
(McGill Pain Questionnaire, Spanish version [30]) on
rachialgia, medication currently being taken and health-
related quality of life (SF-12), together with information
on days off work due to rachialgia. Additionally, before
beginning treatment, the patients will be asked to fill in a
form on sociodemographic questions. Any adverse effects
of the study techniques, and any use of rescue medication
by the patient will also be recorded. During the initial
evaluation, an anamnesis will be obtained on the charac-
teristics of the rachialgia, and note will be taken of the
duration of the pain. In each treatment session, the thera-
pist will record the five pain-related variables that consti-
tute the Lattinen test (LT), which is widely used in pain
treatment clinics in Spain [31]. These variables are: pain
intensity, pain frequency, consumption of analgesics,
level of activity, and nocturnal hours' sleep. Each item is
scored on a Likert scale from 0 to 4; thus, the sum of the
five variables may range from 0 to 20 points, with higher
scores reflecting greater pain severity. In addition, the
Flow diagram for the study Figure 1
Flow diagram for the study. Work scheme with descrip-
tion of assessment visits and times.
Patients recruited with 
uncomplicated chronic 
rachialgia
N = 400 
randomized patients
Baseline evaluation (T0)
True auricular pressure 
group
N = 200
8 sessions
Placebo auricular pressure 
group
N = 200
8 sessions
Final evaluation (T1)
(Week 9)
Final evaluation (T1)
(Week 9)
Follow-up evaluation (T2)
(6 months)
Follow-up evaluation (T2)
(6 months)BMC Complementary and Alternative Medicine 2008, 8:36 http://www.biomedcentral.com/1472-6882/8/36
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auricular points selected for each patient will be recorded
(Table 1).
Primary outcome measure
Changes in pain intensity, measured on the 100 mm vis-
ual analogue scale (VAS) [32], at 9 weeks after beginning
treatment.
Secondary outcome measures
▪ Changes in pain intensity, measured on the 100 mm
VAS, at 6 months after beginning treatment.
▪ Changes in the McGill Pain Questionnaire (MPQ), at the
end of treatment and after 6 months. The MPQ pain eval-
uation index consists of 64 pain descriptors divided into
19 subclasses. Within each subclass, the descriptors are
classified by intensity.
▪ Satisfaction on the improvement perceived by the
patient (PPI) [33], scored by the patient on a 7-point Lik-
ert scale as follows: 1 = extremely satisfied; 2 = very satis-
fied; 3 = moderately satisfied; 4 = no strong feelings either
way; 5 = somewhat unsatisfied; 6 = very unsatisfied; 7 =
extremely unsatisfied.
▪ Changes in health-related quality of life, according to the
Spanish version of the 12-item Short Form health survey,
Version 2, at the end of treatment and after 6 months. This
questionnaire is of a generic type, derived from SF-36,
which has been validated for use in Spain [34], and which
enables the quantification of quality of life in 8 dimen-
sions (physical function, physical role, pain, general
health, vitality, social function, emotional role, mental
health) and expresses two summary components (physi-
cal and mental).
▪ Changes in the results of the Lattinen test and in the con-
sumption of analgesics and NSAIDs (whether or not pre-
scribed by the GP), at the time of randomization, after
each treatment session, at the end of treatment and after 6
months.
Control of blinding and assessment of treatment credibility
The patients will be asked to answer the following ques-
tions:
￿ Expectations and confidence in the treatment (ECT),
evaluated after the third auricular pressure session, and
scored on the original scale of Borkovec and Nau [35]
with four items, scored on a numerical scale of 0 to 10 (0:
totally disagree; 10: totally agree): (1) Are you confident
that this treatment will relieve the pain you feel?; (2) Does
the treatment seem to be a logical one?; (3) Would you
recommend this treatment to a friend or relative suffering
the same complaint?; (4) Do you believe this treatment
would be a possible option for dealing with other prob-
lems?
￿ Verification of the patient's blinding (VB) [36]. After the
final treatment session, the patient will be asked: "What
treatment do you think you were given?" The possible
answers are: 1 = true auricular pressure; 2 = sham auricular
pressure; 3 = Not sure.
Sociodemographic variables
The following data on sociodemographic variables will be
recorded: age, race, sex, marital status, educational level,
financial level and occupational activity.
Table 1: Data collection schedule. Measurement times and variables used in the study.
Visit No. T0 Weekly treatment T1 T2
Week No. 0 123456789 2 4
Data provided by the patient
Pain intensity (VAS 100 mm) X X X
Multidimensional pain evaluation (MPQ-SV) X X X
Quality of life (SF-12) X X X
Analgesics and antiinflammatory drugs prescribed X X X
Sociodemographic variables X
Credibility and expectations X
Improvement perceived by the patient X
Assessment of blinding effectiveness X
Data provided by the therapist
M u l t i d i m e n s i o n a l  p a i n  e v a l u a t i o n  ( L T ) X XXXXXXXXX X
A u r i c u l a r  p o i n t s  u s e d XXXXXXXXX
A d v e r s e  e v e n t s XXXXXXXXX
Economic evaluation
Direct and indirect costs: healthcare professionals and patients X X X
VAS 100 mm: Visual analogue scale (0–100 mm); MPQ-SV: McGill Pain Questionnaire, Spanish version; LT: Lattinen testBMC Complementary and Alternative Medicine 2008, 8:36 http://www.biomedcentral.com/1472-6882/8/36
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Data collection and analysis
Data collection
The data will be compiled in a general questionnaire
addressing each of the study variables, both in the self-
administered formats and in those applied by direct
observation. These data will be sent to the study coordina-
tor at the end of the follow-up evaluation of each patient.
Recording study data and information on adverse effects
A record will be kept of any side effects experienced, and
of possible adverse events arising from either the experi-
mental or the pharmacological treatment.
Statistical analysis
A comparison will be made of the baseline variables for
each of the groups, to test the homogeneity obtained from
the random allocation to groups, in terms of differences of
the means and of proportions. The magnitude of the dif-
ference in the possible imbalance produced by the ran-
dom allocation between the two groups will be quantified
in terms of ratios of the means and of proportions (using
that of the placebo group as a reference level), and the
final adjustment will be made by secondary analyses with
multiple linear regression models.
In the unadjusted analysis, significance tests will be per-
formed for comparison among k samples (parametric or
otherwise, depending on whether or not the distribution
of the outcome variables is asymmetric, and on the homo-
geneity of their variances), taking that of the placebo
group as a reference level, and using comparison tests for
differences of the means in the primary outcome measure
(pain intensity on the 100 mm VAS), both for the inter-
group comparisons (for independent samples) and for
comparisons between the initial and final levels in each
group (in this case, using tests for non-independent or
paired samples).
Linear regression models will be constructed for the pri-
mary outcome measure, adjusted by the baseline level and
using ITT analysis. The group variables will be included,
taking that of the placebo group as a reference level,
together with the results recorded by the medical profes-
sionals, and the sociodemographic data (age and sex),
and the baseline levels for the variables related to the
severity of the process (pain intensity and frequency).
Adjustments will be made for possible confounders, using
criteria of statistical significance and of confusion. The
detection of possible interactions with the treatment
group variable will be evaluated using criteria of statistical
significance for the corresponding interaction terms. The
level of statistical significance will be set at α < 0.05. The
model will be reconstructed, removing the observations
with Cook's distances exceeding the 90th percentile of the
distribution, in order to test the consistency of the results.
An economic analysis will also be carried out, from the
standpoint of the interests of the Andalusian Public
Health System.
Discussion
This is an experimental study in which treatment with
auricular implants is compared with that given to a pla-
cebo group, set up in such a way that the patient has the
sensation of being given the real treatment. This control
group, due to the fact of receiving specific attention and
due to the effects of sensorial stimulation (the pressure on
the implants) may have some positive results. This cir-
cumstance is contrary to the study's initial hypothesis, but
to some extent reflects the inevitable placebo effect.
In order to obtain a sufficient number of patients, the
study is being carried out at various healthcare clinics. It
will be necessary to perform a stratification function so
that all the clinics will receive equal proportions of
patients in each of the two treatment branches. The
patients will be asked not to obtain any kind of alternative
treatment, but they will be allowed to continue taking any
analgesic or anti-inflammatory medication needed,
depending on the pain intensity experienced.
An important limitation that may affect this study is that
of non-compliance with the prescribed treatment;
patients might not attend a treatment session for any of
several possible reasons. The principle outcome measure
will be based on ITT, but a per protocol analysis will also
be performed.
The sample size has been calculated on the assumption of
a 30% drop out rate, but it will be necessary to ascertain
that no differential losses occur between the two treat-
ment branches.
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